Clinical Trial Update: A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating pharmacokinetics, whole-body/organ dosimetry, and biodistribution of fission-derived iodine-131 tositumomab (BEXXAR) in patients with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Non-hodgkin Lymphoma
• Transformed Non-hodgkin Lymphoma

Drugs mentioned

• BEXXAR (tositumomab) with I-131 (tositumomab with iodine-131)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lymphoma, Follicular | Phase 1 | Status: COMPLETED | Results posted: 2012-04-23